Nirvana Life Sciences Inc. reported that it has filed a provisional patent application for a novel process for the isolation of a psychedelic 4-PO-Psilocin compound. The process, developed by Nirvana's Head of Innovation, Robert August allows for the isolation of 4- PO-Psilocin, a substituted tryptamine and psychoactive prodrug that is produced alongside psilocybin and psilocin. Its pharmacological effects are virtually identical to those produced by psilocybin since both are prodrugs.

Both are metabolized in the human body to produce the psychoactive compound psilocin, which is responsible for the majority of psychoactive effects. The 4-PO-Psilocin can be purified by crystallization to an API. It can also be converted to a biologically active and water-soluble salt to yield a final compound 4-PO-Psilocin with a purity greater than 99%.

The ability to convert the 4-PO-Psilocin compound into a water-soluble salt will change the current landscape of delivery systems in the psychedelic sector. The high rate of bioavailability will lower the required volume of psychedelic compound to achieve the same result. This will substantially increase the efficacy and safety in administering psychedelic compounds in clinical settings.